TMEM205 Reduces the Sensitivity of Gastric Cancer to Cisplatin Through TAM/M2 Polarization

Abstract

Cisplatin (DDP) is a basic chemotherapy drug for gastric cancer (GC). With the increase of DDP drug concentration in clinical treatment, cancer cells gradually became resistant. Therefore, it is necessary to find an effective therapeutic target to enhance the sensitivity of GC to DDP. Transmembrane protein 205 (TMEM205) plays significant roles in DDP resistance, but the specific mechanism of TMEM205 in DDP-resistant GC has not been studied. Databases showed that TMEM205 overexpresses in GC. In vitro results showed that TMEM205 enhances proliferation, stemness, epithelial-mesenchymal transition (EMT) process, migration and angiogenesis of SGC-7901/DDP cells by activating the Wnt/β-catenin signaling pathway. In addition, TMEM205 promotes GC progression by inducing M2 polarization of tumor-associated macrophages (TAMs). These results suggest that TMEM205 may be an effective target to regulate the sensitivity of GC to DDP, providing a new therapeutic direction for clinical treatment.